TD Cowen analyst Tyler Van Buren has maintained their bullish stance on ORKA stock, giving a Buy rating on October 28.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Tyler Van Buren has given his Buy rating due to a combination of factors related to Oruka Therapeutics’ promising advancements in their lead monoclonal antibodies for psoriasis treatment. The ORKA-001 antibody has demonstrated an impressive ~100-day half-life, suggesting the potential for once-yearly dosing, which could significantly enhance patient convenience and treatment adherence. This development positions Oruka as a unique player in the biotech space with a differentiated product compared to existing treatments like Skyrizi, especially considering the clean safety profile observed in Phase I trials.
Furthermore, Oruka is making significant strides with their second program, ORKA-002, which targets IL-17A/F and is supported by promising PASI 100 rates seen with similar treatments. The upcoming Phase II trials for both ORKA-001 and ORKA-002, along with the anticipated data on dosing intervals and efficacy, provide a strong foundation for future growth and potential market impact. These factors collectively underpin Van Buren’s optimistic outlook and Buy rating for Oruka Therapeutics.
In another report released on October 28, Barclays also maintained a Buy rating on the stock with a $48.00 price target.